Potent P2Y12 inhibitors, such as prasugrel and ticagrelor, are increasingly used in CCS patients undergoing PCI. In this study, there were no differences between potent P2Y12 inhibitors and clopidogrel in terms of ischemic and bleeding events at one year. https://t.co/QOraGaVcrl
ANTIPLATELET THERAPY AFTER PCI: A State-of-the-Art review that summarises the evidence, discusses current and future directions of antiplatelet treatment regimens after PCI. #EIJBestOf#EAPCI#Cardiotwitter @dominickAngiolillo @mattiaGalli10@DrM_ODonoghue https://t.co/V23KEyH3Jc
@remzi_sarikaya Surgical removal of this large mobile thrombus would be more accurate. Ventriculotomy has been a commonly performed procedure for LV thrombus however left atrial approach does not require incision to the LV thus theoretically preserves the remaining LV function, good luck
@remzi_sarikaya ST elevation in aVR > in V1, LMCA disease should be considered (sensitivity and specificity >%80)
If a ST elevation of at least 0.5 mm is seen in aVR in a patient with non-STemı like in this case , LMCA or 3-vessel disease should be considered (sensitivity 78%, specificity >86%)
Choosing the right P2Y12 inhibitor after an #ACS across the ischemic and bleeding risk spectrum, according to the PRAISE risk score: https://t.co/qKzqQk2cgE
#CVD#DAPT#EHJQCCO@cpgale3@diogoasantosfer
@MDcardionur @MubarakAlhatemi@smithECGBlog@EM_RESUS The post was about the ECG. This is not the ECG of Ebstein. Not sure what x-ray you saw....but ECG is not of Ebstein....